Alexandra M Nanzer, Anne-Catherine Maynard-Paquette, Vardah Alam, Linda Green, Louise Thomson, Jodie Lam, Mariana Fernandes, Cris Roxas, Grainne d'Ancona, Andrew Hearn, Jessica Gates, Sangita Agarwal, Brian D Kent, Michelle Fernando, David P D'Cruz, Claire Hopkins, Tevfik F Ismail, Jaideep Dhariwal, David J Jackson
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multi-systemic disease characterised by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5-receptor monoclonal antibody, induces rapid depletion of eosinophils; its longer-term effect in EGPA is unknown. OBJECTIVE: To assess the real-world effectiveness and clinical remission rates of anti-IL5R therapy in EGPA METHODS: We performed a retrospective cohort analysis of EGPA patients, who commenced treatment with benralizumab...
January 9, 2024: Journal of Allergy and Clinical Immunology in Practice